Phenelzine

Medical uses

Phenelzine is primarily used in the treatment of major depressive disorder. Patients with atypical depression respond particularly well to phenelzine, but evidence suggests phenelzine can also be effective in melancholic depressions. The medication is also useful in treatment-resistant depression, where patients do not respond favorably to first and second-line treatments for depression. In addition to being a recognized treatment for major depressive disorder, phenelzine is also effective in treating dysthymia, bipolar depression, panic disorder, social anxiety disorder, bulimia nervosa, post-traumatic stress disorder (PTSD), and obsessive–compulsive disorder (OCD).

Side effects

Common side effects of phenelzine may include dizziness, blurry vision, dry mouth, headache, lethargy, sedation, somnolence, insomnia, anorexia, weight gain or loss, small fiber neuropathy, nausea and vomiting, diarrhea, constipation, urinary retention, mydriasis, muscle tremors, hyperthermia, sweating, hypertension or hypotension, orthostatic hypotension, paresthesia, hepatitis, and sexual dysfunction (consisting of loss of libido and anorgasmia). Rare side effects usually only seen in susceptible individuals may include hypomania or mania, psychosis, and acute liver failure, the last of which is usually only seen in people with pre-existing liver damage, old age, long-term effects of alcohol consumption, or viral infection.

Interactions

The MAOIs have certain dietary restrictions and drug interactions. A hypertensive crisis may result from the overconsumption of tyramine-containing foods, although it is a rare occurrence. Serotonin syndrome may result from an interaction with certain drugs which increase serotonin activity such as selective serotonin reuptake inhibitors, serotonin releasing agents, and serotonin agonists.

Phenelzine has also been linked to vitamin B6 deficiency. Transaminases such as GABA-transaminase have been shown to be dependent upon vitamin B6 and may be involved in a potentially related process, since the phenelzine metabolite phenylethylidenehydrazine (PEH) is a GABA-transaminase inhibitor. Both phenelzine and vitamin B6 are rendered inactive upon these reactions occurring. The pyridoxine form of B6 is recommended for supplementation, since this form has been shown to reduce hydrazine toxicity from phenelzine and, in contrast, the pyridoxal form has been shown to increase the toxicity of hydrazines.

Pharmacology

Pharmacodynamics

Phenelzine is a non-selective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It inhibits both of the respective isoforms of MAO, MAO-A and MAO-B, and does so almost equally, with a slight preference for the former. By inhibiting MAO, phenelzine prevents the breakdown of the monoamine neurotransmitters serotonin, melatonin, norepinephrine, epinephrine, and dopamine, as well as the trace amine neuromodulators such as phenethylamine, tyramine, octopamine, and tryptamine. This leads to an increase in the extracellular concentrations of these neurochemicals and, therefore, an alteration in neurochemistry and neurotransmission. This action is thought to be the primary mediator in phenelzine's therapeutic benefits.

Phenelzine and its metabolites also inhibit at least two other enzymes to a lesser extent, of which are alanine transaminase (ALA-T), and γ-aminobutyric acid transaminase (GABA-T), the latter of which is not caused by phenelzine itself, but by a phenelzine metabolite phenylethylidenehydrazine (PEH). By inhibiting ALA-T and GABA-T, phenelzine causes an increase in the alanine and GABA levels in the brain and body. GABA is the major inhibitory neurotransmitter in the mammalian central nervous system, and is very important for the normal suppression of anxiety, stress, and depression. Phenelzine's action in increasing GABA concentrations may significantly contribute to its antidepressant, and especially, anxiolytic/antipanic properties, the latter of which have been considered superior to those of other antidepressants. As for ALA-T inhibition, though the consequences of disabling this enzyme are currently not well understood, there is some evidence to suggest that it is this action of the hydrazines (including phenelzine) which may be responsible for the occasional incidence of hepatitis and liver failure.

Phenelzine has also been shown to metabolize to phenethylamine (PEA). PEA acts as a releasing agent of norepinephrine and dopamine, which occurs in a similar manner to amphetamine by being taken up into vesicles, displacing and causing the release of those monoamines, and reversing monoamine flux through their respective transporters (though with markedly shorter pharmacokinetics).

Like many other antidepressants, phenelzine usually requires several weeks of treatment to achieve full therapeutic effects. The reason for this delay is not fully understood. Still, it is believed to be due to many factors, including achieving steady-state levels of MAO inhibition and the resulting adaptations in mean neurotransmitter levels, the possibility of necessary desensitization of autoreceptors which generally inhibit the release of neurotransmitters like serotonin and dopamine, and also the upregulation of enzymes such as serotonin N-acetyltransferase. Typically, a therapeutic response to MAOIs is associated with an inhibition of at least 80-85% of monoamine oxidase activity.

Pharmacokinetics

Phenelzine is metabolized primarily in the liver, and its metabolites are excreted in the urine. Oxidation is the primary routine of metabolism, and the major metabolites are phenylacetic acid and parahydroxyphenylacetic acid, recovered as about 73% of the excreted dose of phenelzine in the urine over 96 hours after single doses. Acetylation to N2-acetylphenelzine is a minor pathway. Phenelzine may also interact with cytochrome P450 enzymes, inactivating these enzymes through the formation of a heme adduct. Two other minor metabolites of phenelzine, as mentioned above, include phenylethylidenehydrazine and phenethylamine.

Chemistry

Phenelzine, also known as 2-phenylethylhydrazine or phenylethylamine hydrazide, is a phenethylamine and hydrazine derivative. It is the hydrazide of β-phenethylamine and can also be referred to as N-aminophenethylamine.

Close analogues of phenelzine include the amphetamine and hydrazine derivatives pheniprazine (α-methylphenelzine; the corresponding amphetamine analogue) and metfendrazine (α,N-dimethylphenelzine; the corresponding methamphetamine analogue), among others.

Research

Phenelzine showed promise in a phase II clinical trial from March 2020 in treating prostate cancer.

• Phenelzine has also been shown to have neuroprotective effects in animal models.

References

References

1. (3 March 2020). "Phenelzine (Nardil) Use During Pregnancy".
2. Anvisa. (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
3. "Phenelzine". U.S. National Library of Medicine.
4. (2023). "StatPearls". StatPearls Publishing.
5. (1996). "[[The Merck Index]]". Merck & Co.
6. (1932). "Sur la β-phenoéthylhydrazine.". Collection of Czechoslovak Chemical Communications.
7. Parke-Davis Division of Pfizer Inc.. (2007). "Nardil(R) (Phenelzine sulfate tablets, USP), labeling information". U.S. Food and Drug Administration's.
8. (August 2023). "On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression". Psychopharmacology Bulletin.
9. Van den Eynde, Vincent. (2023). "The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression". CNS spectrums.
10. (July 2004). "The role of monoamine oxidase inhibitors in current psychiatric practice". Journal of Psychiatric Practice.
11. (November 1987). "Double-blind study of imipramine versus phenelzine in Melancholias and Dysthymic Disorders". The British Journal of Psychiatry.
12. (March 1981). "Monoamine oxidase inhibitors in bipolar endogenous depressives". Journal of Clinical Psychopharmacology.
13. (February 1987). "Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks". The Journal of Clinical Psychiatry.
14. (2003). "Pharmacological treatment of social anxiety disorder: a meta-analysis". Depression and Anxiety.
15. (May 1988). "Phenelzine vs placebo in 50 patients with bulimia". Archives of General Psychiatry.
16. (October 1988). "A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder". The American Journal of Psychiatry.
17. (November 1992). "Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial". The British Journal of Psychiatry.
18. (July 2021). "Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine". Journal of Clinical Psychopharmacology.
19. (April 1996). "Phenelzine-induced fulminant hepatic failure". Annals of Internal Medicine.
20. (January 2019). "The risk of harm from acute tyramine-induced hypertension: how significant?". PsychoTropical Commentaries.
21. (March 2012). "Practical guide for prescribing MAOIs: debunking myths and removing barriers". CNS Spectrums.
22. (2019). "Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions". International Journal of Tryptophan Research.
23. (2013). "Serotonin syndrome". Ochsner Journal.
24. (November 1994). "Phenelzine reduces plasma vitamin B6". Journal of Psychiatry & Neuroscience.
25. (January 2004). "Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin". The Journal of Biological Chemistry.
26. (July 1960). "Effect of forms of vitamin B6 on acute toxicity of hydrazines". Toxicology and Applied Pharmacology.
27. (November 1992). "Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review". Journal of Psychiatry & Neuroscience.
28. (August 2001). "Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain". Cellular and Molecular Neurobiology.
29. (1994). "Amine Oxidases: Function and Dysfunction".
30. (1998). "The Antipanic Drug Phenelzine and Its Effects on GABA and Related Amino Acids". University of Alberta.
31. (April 1996). "Phenelzine-induced fulminant hepatic failure". Annals of Internal Medicine.
32. (June 1985). "Formation of beta-phenylethylamine from the antidepressant, beta-phenylethylhydrazine". Biochemical Pharmacology.
33. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
34. (1981). "Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo". Neuropsychobiology.
35. "Phenelzine".
36. "Phenelzine: Package Insert".
37. "NARDIL- phenelzine sulfate tablet, film coated".
38. (June 2016). "Highly sensitive LC-MS/MS-ESI method for determination of phenelzine in human plasma and its application to a human pharmacokinetic study". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences.
39. (May 2006). "An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid". British Journal of Clinical Pharmacology.
40. (January 2022). "Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine". Cellular and Molecular Neurobiology.
41. (4 August 2024). "PiHKAL·info".
42. (2011). "[[The Shulgin Index". Transform Press.
43. (2011). "The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents". Curr Med Chem.
44. (2012). "History and therapeutic use of MAO-A inhibitors: a historical perspective of MAO-A inhibitors as antidepressant drug". Curr Top Med Chem.
45. (May 2019). "Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine". Chemico-Biological Interactions.
46. (January 2022). "Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine". Cellular and Molecular Neurobiology.
47. (April 2017). "Phenelzine Protects Brain Mitochondrial Function In Vitro and In Vivo following Traumatic Brain Injury by Scavenging the Reactive Carbonyls 4-Hydroxynonenal and Acrolein Leading to Cortical Histological Neuroprotection". Journal of Neurotrauma.